Medical Pharmacology and Therapeutics Elsevier eBook on Vitalsource, 5th Edition

by Derek G. Waller, BSc, DM, MBBS, FRCP and Anthony Sampson, MA, PhD, FHEA, FBPhS

Elsevier eBook on VitalSource

ISBN: 9780702071935

Publication Date: 08-02-2017

Page Count: 744

Imprint: Elsevier

List Price: $67.99

Most review copies are eBooks – how fast!

A review copy request is most likely to be fulfilled as an eBook on VitalSource rather than a print product, unless no eBook is available. eBooks become available in as little as a few hours. Print products will take between 7 and 10 days to arrive. To request a print copy, please contact us through the Evolve Support Center for further assistance or contact your Elsevier Sales Rep.

An Access Code

Important note

You are viewing the faculty version.

Students requesting access will be reported.

Student access

Technical Support

Contact your Elsevier Sales Rep to learn more about adopting this product

Medical Pharmacology and Therapeutics, now in its fifth edition, offers medical students all they need to know to become safe and effective prescribers. It forms a complete, integrated resource for basic pharmaceutical science, pathophysiology, clinical pharmacology, and therapeutics.

Key Features
- Clear, disease-based approach
- Presentation of how drugs are used in clinical practice
- Succinct explanations of the major pathogenic mechanisms of each disease and consequent clinical signs and symptoms
- Comprehensive reviews of major drug classes relevant to each disease
- Structured approach to the principles of disease management – outlining core principles of drug choice and planning a therapeutic regimen for common diseases
- Quick-reference drug compendia illustrating key similarities and differences among all BNF-listed drugs in each class
Related Products
- 5th Edition
  Evolve Resource for Medical Pharmacology & Therapeutics
  Resources
  
  ISBN: 9780702071928
Contents

SECTION 1 General principles
1. Principles of pharmacology and mechanisms of drug action
2. Pharmacokinetics
3. Drug discovery, safety and efficacy
4. The nervous system, neurotransmission and the peripheral autonomicnervous system

SECTION 2 The cardiovascular system
5. Ischaemic heart disease
6. Systemic and pulmonary hypertension
7. Heart failure
8. Cardiac arrhythmias
9. Cerebrovascular disease and dementia
10. Peripheral vascular disease
11. Haemostasis

SECTION 3 The respiratory system
12. Asthma and chronic obstructive pulmonary disease
13. Respiratory disorders: cough, respiratory stimulants, cysticfibrosis and neonatal respiratory distress syndrome

SECTION 4 The renal system
14. Diuretics
15. Disorders of micturition
16. Erectile dysfunction

SECTION 5 The nervous system
17. General anaesthetics
18. Local anaesthetics
19. Opioid analgesics and the management of pain
20. Anxiolytics, sedatives and hypnotics
21. The major psychotic disorders: schizophrenia and mania
22. Depression, attention deficit hyperactivity disorder and narcolepsy
23. Epilepsy
24. Extrapyramidal movement disorders and spasticity
25. Other neurological disorders: multiple sclerosis, motor neuron diseaseand Guillain–Barré syndrome
26. Migraine

SECTION 6 The musculoskeletal system
27. The neuromuscular junction and neuromuscular blockade
28. Myasthenia gravis
29. Non-steroidal anti-inflammatory drugs
30. Rheumatoid arthritis, other inflammatory arthritides and osteoarthritis
31. Hyperuricaemia and gout

SECTION 7 The gastrointestinal system
32. Nausea and vomiting
33. Dyspepsia and peptic ulcer disease
34. Inflammatory bowel disease
35. Constipation, diarrhoea and irritable bowel syndrome
36. Liver disease
37. Obesity

SECTION 8 The immune system
38. The immune response and immunosuppressant drugs
39. Antihistamines and allergic disease

SECTION 9 The endocrine system and metabolism
40. Diabetes mellitus
41. The thyroid and control of metabolic rate
42. Calcium metabolism and metabolic bone disease
43. Pituitary and hypothalamic hormones
44. Corticosteroids (glucocorticoids and mineralocorticoids)
45. Female reproduction
46. Androgens and anabolic steroids
47. Anaemia and haematopoietic colony-stimulating factors
48. Lipid disorders

SECTION 10 The skin and eyes
49. Skin disorders
50. The eye

SECTION 11 Chemotherapy
51. Chemotherapy of infections
52. Chemotherapy of malignancy

SECTION 12 General features: toxicity and prescribing
53. Drug toxicity and overdose
54. Substance abuse and dependence
55. Prescribing, adherence and information about medicines
56. Drug therapy in special situations
Authors

Derek G. Waller, BSc, DM, MBBS, FRCP, Former Consultant Physician and Senior Clinical Lecturer, Department of Medicine, University Hospital Southampton, Southampton, UK and Anthony Sampson, MA, PhD, FHEA, FBPhS, Professorial Fellow in Clinical Pharmacology & Director of Undergraduate Programmes, Faculty of Medicine, University of Southampton
Southampton, United Kingdom
Accessibility
- Ways of Reading
  - The appearance of the text and page layout can be modified according to the capabilities of the reading system (font family and font size, spaces between paragraphs, sentences, words, and letters, as well as color of background and text)
  - This e-publication is accessible to the full extent that the file format and types of content allow, on a specific reading device, by default, without necessarily including any additions such as textual descriptions of images or enhanced navigation
  - No information about nonvisual reading is available
- Conformance
  - No information is available
- Navigation
  - Table of contents to all chapters of the text via links
  - Page list to go to pages from the print source version
- Rich Content
  - No information is available
- Hazards
  - No information is available
- Product Content
  - No information is available
- Legal Considerations
  - No information is available
- Additional Accessibility Information
  - Page breaks included from the original print source
  - For readers with color vision deficiency, use of color (e.g., in diagrams, graphics and charts, in prompts, or on buttons inviting a response) is not the sole means of graphical distinction or of conveying information
  - E-publication includes basic navigation (usually less detailed than TOC-based navigation)
  - Where links, controls or buttons are included in the content, the purpose or functionality of each link, control or button is apparent from the associated text alone - or where it is unclear, separate link, control or button descriptions are provided
  - All (or substantially all) textual matter is arranged in a single logical reading order (including text that is visually presented as separate from the main text flow, e.g., in boxouts, captions, tables, footnotes, endnotes, citations, etc.). Non-textual content is also linked from within this logical reading order. (Purely decorative non-text content can be ignored).
  - The language of the text has been specified (e.g., via the HTML or XML lang attribute) to optimise text-to-speech (and other alternative renderings), both at the whole document level and, where appropriate, for individual words, phrases or passages in a different language.